fda warning letters compounded semaglutide tirzepatide 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Issues 30 Warning Letters

Explore the pros and cons of GLP-1 drugs in managing diabetes and obesity, balancing benefits like weight loss against side effects and costs

But several factors work against this natural recovery process, including age (collagen production drops roughly 1% per year after age 20), the amount of weight lost (more than 50 pounds creates significantly more laxity), how long the excess weight was carried, sun damage history, smoking, genetics, and the speed at which the weight came off

If you choose Wegovy or Ozempic for your medical weight loss in Seattle, you will fill your prescription through a pharmacy

This release upon injury points to a central role in the body's endogenous repair cascade

learn more by reading the medication guides for Xenical and Alli